April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Mechanisms Of Neuroprotective Phosphine-Borane Complexes PB1 And PB2
Author Affiliations & Notes
  • Alex F. Thompson
    Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin
  • Christopher J. Lieven
    Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin
  • Alex M. Dins
    Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin
  • Leonard A. Levin
    Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin
    Ophthalmology, University of Montreal, Montreal, Quebec, Canada
  • Footnotes
    Commercial Relationships  Alex F. Thompson, None; Christopher J. Lieven, None; Alex M. Dins, None; Leonard A. Levin, Wisconsin Alumni Research Foundation (P)
  • Footnotes
    Support  NIH R21EY017970 and P30EY016665, an unrestricted departmental grant from Research to Prevent Blindness, Inc, and a Wisconsin Alumni Research Foundation Lead Discovery Initiative Grant
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 5435. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alex F. Thompson, Christopher J. Lieven, Alex M. Dins, Leonard A. Levin; Mechanisms Of Neuroprotective Phosphine-Borane Complexes PB1 And PB2. Invest. Ophthalmol. Vis. Sci. 2011;52(14):5435.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Novel reducing agents bis (3-propionic acid methyl ester) phenylphosphine borane complex (PB1) and (3-propionic acid methyl ester) diphenylphosphine borane complex (PB2) are neuroprotective in cultured retinal ganglion cells subjected to axonal injury (Schlieve, Exp Eye Res 83:1252, 2006) and RGC-5 cells treated with mitochondrial electron transport chain inhibitors (Seidler, ACS Chem Neurosci 1:95-103, 2010). To understand the mechanism by which these compounds are neuroprotective, we investigated their activities as free radical scavengers.

Methods: : Superoxide was generated using xanthine/xanthine oxidase (XO) in the presence of dihydroethidium (HEt). HEt reacts with superoxide to form the fluorescent product 2-hydroxyethidium (OH-Et). fluorescence was assessed 30 minutes after reaction initiation using a fluorescence plate reader at 405 nm excitation / 562 nm emission. This excitation is relatively specific for OH-Et and poorly excites ethidium, the oxidation product of HEt. Electron paramagnetic resonance (EPR) spectrometry was used to confirm results seen with HEt. Hypoxanthine and XO were combined with the spin trap DEPMPO. Signal from the adduct formed by DEPMPO and superoxide was measured 20 minutes after reaction initiation with a 1420 Victor 2 T Multilabel Counter.

Results: : Addition of 300 U/mL polyethylene glycol-conjugated superoxide dismutase, a known scavenger of superoxide, to xanthine, XO and HEt reduced OH-Et fluorescence by 90.7±0.4% (p < 0.0001). Contrastingly, PB1 and PB2 do not limit OH-Et fluorescence. Addition of 10 µM PB1 or PB2 did not reduce fluorescence, indicating a lack of scavenging activity. In EPR studies, addition of SOD eliminates the superoxide-DEPMPO adduct signal, demonstrating that SOD scavenges generated superoxide. When PB1 or PB2 were added to the EPR reaction, the superoxide signal was not eliminated. Instead, a signal identical to that of a hydroxyl-DEPMPO adduct was seen, consistent with chemical reduction of the superoxide-DEPMPO adduct.

Conclusions: : Neuroprotective phosphine-borane complexes do not scavenge superoxide. These findings are consistent with our hypothesis that PB1 and PB2 are neuroprotective as a result of their ability to chemically reduce intracellular signaling molecules.

Keywords: neuroprotection • oxidation/oxidative or free radical damage • apoptosis/cell death 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×